Health & Biotech
Creso Pharma (ASX:CPH) is a global medicinal cannabis innovator that develops cannabis and hemp-derived therapeutic, nutraceutical and lifestyle products for both people and animals.
Founded by a team of highly experienced pharmaceutical executives, Creso set out to leverage cutting edge science and research to develop, register and commercialise innovative cannabis and hemp derived products.
It was the first company to import medical cannabis to Australia and it has a presence across Canada, under its subsidiary Mernova, Switzerland and the EU, Israel, Latin America and Australia.
From the outset, Creso’s goal has been to become the world’s most trusted supplier of cannabis and hemp derived products. The company’s experienced pharmaceutical leadership team have an unparalleled track record of success commercialising a wide range of pharmaceutical and therapeutic solutions.
Creso can deliver products with standardised dosing and formulations through the application of pharmaceutical rigour, Good Manufacturing Practices (GMP) standards when appropriate and proprietary, innovative delivery technologies.
As a global company, Creso is not limited by any single market. This enables Creso to offer a diverse portfolio of solutions to the widest possible population.
By partnering with leading global companies in critical areas of research and product development, manufacturing and distribution, Creso has been able to accelerate the development and distribution of approved products allowing for broad access by patients and consumers.
KEY PEOPLE
RELATED STOCKHEAD STORIES
News
ASX Meme Stocks: Just how have they turned out for investors who took the plunge?
Health & Biotech
ASX Health Stocks: Imugene up on PD1-Vaxx cancer study expansion plans
Explainers
CBD Oil: The ultimate investor’s guide to a potential $64 billion global market
Health & Biotech
Creso Pharma expands European footprint with additional hemp seed oil purchase orders
Health & Biotech
ASX Pot Stocks: Roto-Gro jumps on Canniberia’s pre-approval for cannabis cultivation
Health & Biotech
ASX Health Stocks: Beamtree gets on the M&A trail while Creso Pharma eyes NASDAQ listing
Health & Biotech
Creso Pharma and Red Light Holland call off merger, as NASDAQ beckons
Mining
ASX Pot Stocks: BOD Australia jumps 12% on record $7.52 million revenue for FY21
Health & Biotech
Creso Pharma’s psychedelics subsidiary Halucenex receives Canadian licence approval, targets Phase II trials on PTSD
News
Weed Week: Cannabis ice cream deal and Israeli CBD market worth US$475m by 2025
Health & Biotech
ASX health stocks: Rhinomed rockets 80% after securing first government purchase for COVID-19 Rhinoswabs
Health & Biotech
Creso Pharma’s Canadian subsidiary Mernova secures licence for medicinal cannabis in Canada
News
Closing Bell: The ASX makes a strong start to August, closes 1.3% higher
Health & Biotech
ASX Cannabis Stocks: Creso pops on 450pc annual revenue increase
News
Market Highlights and 5 ASX Small Caps to watch on Monday
Health & Biotech
Creso Pharma subsidiary plans to introduce new lines of super-potent pot
Health & Biotech